Abstract:Liver fibrosis affects millions of people worldwide and is rising vastly over the past decades. With no viable therapies available, liver transplantation is the only curative treatment for advanced diseased patients. Excessive accumulation of aberrant extracellular matrix (ECM) proteins, mostly collagens, produced by activated hepatic stellate cells (HSCs), is a hallmark of liver fibrosis. Several studies have suggested an inverse correlation between collagen-I degrading matrix metalloproteinase-1 (MMP-1) serum levels and liver fibrosis progression highlighting reduced MMP-1 levels are associated with poor disease prognosis in patients with liver fibrosis. We hypothesized that delivery of MMP-1 might potentiate collagen degradation and attenuate fibrosis development. In this study, we report a novel approach for the delivery of MMP-1 using MMP-1 decorated polymersomes (MMPsomes), as a surface-active vesicle-based ECM therapeutic, for the treatment of liver fibrosis. The storage-stable and enzymatically active MMPsomes were fabricated by a post-loading of Psomes with MMP-1. MMPsomes were extensively characterized for the physicochemical properties, MMP-1 surface localization, stability, enzymatic activity, and biological effects. Dose-dependent effects of MMP-1, and effects of MMPsomes versus MMP-1, empty polymersomes (Psomes) and MMP-1 + Psomes on gene and protein expression of collagen-I, MMP-1/TIMP-1 ratio, migration and cell viability were examined in TGFβ-activated human HSCs. Finally, the therapeutic effects of MMPsomes, compared to MMP-1, were evaluated in vivo in carbon-tetrachloride (CCl4)-induced early liver fibrosis mouse model. MMPsomes exhibited favorable physicochemical properties, MMP-1 surface localization and improved therapeutic efficacy in TGFβ-activated human HSCs in vitro. In CCl4-induced early liver fibrosis mouse model, MMPsomes inhibited intra-hepatic collagen-I (ECM marker, indicating early liver fibrosis) and F4/80 (marker for macrophages, indicating liver inflammation) expression. In conclusion, our results demonstrate an innovative approach of MMP-1 delivery, using surface-decorated MMPsomes, for alleviating liver fibrosis.

Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs

MMP Enzyme in Tumor Micro-environment: A Promising Target for Nano-medicine Delivery

Matrix metalloproteinases involvement in pathologic conditions

Matrix Metalloproteinases: New Targets in Cancer Therapy

Matrix metalloproteases: variations on a theme

Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

Matrix Metalloproteinase-Responsive Drug Delivery Systems.

Matrix Metalloproteinases in the Periodontium—Vital in Tissue Turnover and Unfortunate in Periodontitis

Matrix metalloproteinases at a glance

Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair

Advances in Clinical Research of Matrix Metalloproteinase Inhibitors as Anticancer Agents

Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal

Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics

Metalloproteinases and Regulation of Endometrial Function

The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases

Regulation on Mechanical Properties of Collagen: Enhanced Bioactivities of Metallofullerol.

Peptides and Peptidomimetics as Inhibitors of Enzymes Involved in Fibrillar Collagen Degradation

Understanding the role of tissue degrading enzymes and their inhibitors in development and disease

Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer

Matrix metalloproteinase-1 decorated polymersomes, a surface-active extracellular matrix therapeutic, potentiates collagen degradation and attenuates early liver fibrosis